
11 Jan 2019 Research
Myelofibrosis: Finding new ways to treat patients
Myelofibrosis is a fatal bone marrow cancer. The disease is caused by excessive secretion of factors by cancerous platelet-producing cells called megakaryocytes. These secretions cause the replacement of normal bone marrow tissue with fibrous scar tissue.
Dr Chen’s team can successfully recreate this pathological bone marrow environment in the laboratory, and their preliminary research data shows that reduced levels of a protein complex called FANCcore leads to more myelofibrosis.
Dr Chen’s team hypothesise that loss of the protein complex FANCcore increases the growth of myelfibrosis by altering megakaryocytes. Dr Chen uses both human tissue cultures and mouse models to examine the cellular and molecular changes to megakaryocytes following the absence of the FANCcore complex and to understand how these changes cause myelofibrosis.
The team hopes that by focusing on the role of FANCcore in megakaryocyte biology, they can reveal new ways to treat myelofibrosis.
Related posts
9 November 2017
Leukaemia UK is the new name for the ‘Elimination of Leukaemia Fund’
We are a leading charity making a difference to families affected by leukaemia, lymphoma, myeloma and other blood cancers.
31 October 2023
Chris Dew joins Leukaemia UK as Director of Finances & Resources
Leukaemia UK is delighted to announce the appointment of Chris Dew as Director of Finance & Resources, following ten years as Chief Financial Officer at musical therapy charity Nordoff-Robbins. The…
18 May 2026
A decade on: Dr Javier Redondo Muñoz continues to shape the future of Leukaemia research
Ten years after joining the second cohort of Leukaemia UK’s John Goldman Fellowships (JGF), Dr Javier Redondo Muñoz is continuing to shape the future of leukaemia research. Now leading his own team in…
9 May 2018
Sharing this exciting news: a treatment advance for childhood leukaemia
A deal has been struck to let the NHS offer children an expensive new cancer therapy that has been called the most exciting treatment advance for decades